Q-omics provides the consensus-scored FLCN profile across patient tissues and cancer cell-line models. FLCN expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, FLCN is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, FLCN RNA expression shows 19,578 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUSC, HNSC, and UVM as cancer lineages where FLCN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FLCN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FLCN survival associations across molecular data types. FLCN RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FLCN RNA expression–survival associations across cancer types. High FLCN expression shows unfavorable associations in LUSC, COAD, UVM, LGG and MESO, but favorable associations in BRCA. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LUSC as the clearest survival context for FLCN RNA expression.
This table summarizes FLCN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for FLCN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FLCN shows lower tumor expression in LUAD and LUSC and higher tumor expression in HNSC, KIRC, KIRP and LIHC. The HNSC box plot shows higher FLCN RNA expression in tumor versus normal tissue (log2 FC = +0.916, t-test p < 0.001).
This table shows molecular features associated with FLCN in patient tissues and cancer cell lines. In patient samples, FLCN shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FLCN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
